Roche Holding Company Profile (VTX:ROG)

About Roche Holding (VTX:ROG)

Roche Holding logoRoche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Diversified Electronics
  • Sub-Industry: N/A
  • Symbol: VTX:ROG
  • CUSIP: N/A
  • Web: www.roche.com
Average Prices:
  • 50 Day Moving Avg: CHF 130.25
  • 200 Day Moving Avg: CHF 113.01
P/E:
  • Trailing P/E Ratio: 33.54
  • P/E Growth: 1.66
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: 21.17%
  • Return on Equity: 46.76%
  • Return on Assets: 14.96%
 

Frequently Asked Questions for Roche Holding (VTX:ROG)

What is Roche Holding's stock symbol?

Roche Holding trades on the VTX under the ticker symbol "ROG."

Where is Roche Holding's stock going? Where will Roche Holding's stock price be in 2017?

15 brokers have issued 12-month target prices for Roche Holding's stock. Their predictions range from CHF 203 to CHF 325. On average, they expect Roche Holding's stock price to reach CHF 264.07 in the next year. View Analyst Ratings for Roche Holding.

Who are some of Roche Holding's key competitors?

Who are Roche Holding's key executives?

Roche Holding's management team includes the folowing people:

  • Severin Schwan, Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director
  • Alan Hippe, Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer
  • Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications
  • Sophie Kornowski-Bonnet, Member of the Enlarged Corporate Executive Committee, Head Roche Partnering
  • Osamu Nagayama, Member of the Enlarged Corporate Executive Committee, Chairman and Chief Executive Officer Chugai
  • John C. Reed M.D., Ph.D., Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
  • Michael David Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
  • Cristina A. Wilbur, Member of the Executive Committee, Head Group Human Resources
  • Urs Jaisli, Chief Compliance Officer
  • Gottlieb A. Keller, Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors


MarketBeat Community Rating for Roche Holding (VTX ROG)
Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about Roche Holding and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Roche Holding (VTX:ROG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: CHF 264.07
Consensus Price Target History for Roche Holding (VTX:ROG)
Price Target History for Roche Holding (VTX:ROG)
Analysts' Ratings History for Roche Holding (VTX:ROG)
Show:
DateFirmActionRatingPrice TargetDetails
10/20/2017Morgan StanleySet Price TargetNeutralCHF 260View Rating Details
10/20/2017Kepler Capital MarketsSet Price TargetNeutralCHF 226View Rating Details
10/20/2017Deutsche Bank AGSet Price TargetNeutralCHF 254View Rating Details
10/20/2017HSBC Holdings plcSet Price TargetSellCHF 203View Rating Details
10/19/2017Baader BankSet Price TargetNeutralCHF 231View Rating Details
10/18/2017Citigroup Inc.Set Price TargetNeutralCHF 255View Rating Details
10/18/2017Goldman Sachs Group, Inc. (The)Set Price TargetBuyCHF 325View Rating Details
10/16/2017J P Morgan Chase & CoReiterated RatingBuyView Rating Details
10/16/2017Jefferies Group LLCSet Price TargetBuyCHF 295View Rating Details
10/16/2017Credit Suisse GroupSet Price TargetNeutralCHF 260View Rating Details
9/25/2017BNP ParibasSet Price TargetSellCHF 235View Rating Details
9/13/2017Barclays PLCSet Price TargetBuyCHF 295View Rating Details
8/15/2017Berenberg BankSet Price TargetBuyCHF 273View Rating Details
7/27/2017Sanford C. BernsteinSet Price TargetBuyCHF 284View Rating Details
6/29/2017Societe GeneraleSet Price TargetNeutralCHF 275View Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Roche Holding (VTX:ROG)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Roche Holding (VTX:ROG)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Roche Holding (VTX:ROG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Roche Holding (VTX:ROG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Roche Holding (VTX:ROG)
Latest Headlines for Roche Holding (VTX:ROG)
Source:
Loading headlines, please wait.

Social

Social activity is not available for this stock.
This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.